Nisha Pandey

Health and Me

Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours

Russia's mRNA Cancer Vaccine: First Patient Completes Treatment, Shows No New Tumours

<span>Russia</span> has reported a milestone in its experimental personalised cancer vaccine development. The first patient to complete treatment with the country's mRNA-based cancer vaccine is reportedly doing well as the follow-up scans showed no new tumour growth in the four months after completing therapy.

The update was shared by <span>Alexander Gintsburg</span>, scientific director of Moscow's Gamaleya Research Institute of Epidemiology and Microbiology. 

According to a report published by <em><span rel="noindex">Kursiv</span></em>, the patient is undergoing monthly examinations at Russia's <span>National Medical Research Centre for Radiology</span>, including high-resolution CT scans. Doctors are paying attention to the lymph nodes where cancer is most likely to spread.

The patient will remain under medical observation for the next three years. While the early findings are promising, they are based on a single patient's experience, which is a major limitation.

<h2>Russia's Personalised <span rel="noindex">mRNA Cancer Vaccine</span></h2>

Also read: <a href="https://www.healthandme.com/health-wellness/how-the-conditions-people-live-in-can-quietly-shape-our-risk-of-cancer-article-156502359" data-type="tilCustomLink">How The Conditions People Live In Can Quietly Shape Our Risk Of Cancer</a>

The treatment, known as <span>NeoOncovac</span>, is a personalised <a href="https://www.healthandme.com/health-news/new-pancreatic-cancer-vaccine-triggers-immune-response-in-99-of-patients-article-156449205" data-type="tilCustomLink">cancer vaccine</a> developed with the help of messenger RNA (mRNA) technology.

Unlike preventive vaccines that protect people against infections, therapeutic cancer vaccines are designed to help the immune system recognise and attack existing cancer cells.

The vaccine is customised using the genetic characteristics of an individual's tumour. Researchers analyse tumour samples to identify specific mutations that could help distinguish cancer cells from healthy cells. 

The mRNA is then designed to instruct the body to produce these targets related to tumour, prompting the immune system to recognise and attack the cancer cells. It aims to make the immune response more specific to the patient's cancer rather than targeting all cancer cells.

<h2>Six Patients Received The Vaccine </h2>

Also read: <a href="https://www.healthandme.com/health-news/american-cancer-society-revises-prostate-cancer-screening-guidelines-what-you-need-to-know-article-156505090" data-type="tilCustomLink">American Cancer Society Revises Prostate Cancer Screening Guidelines: What You Need To Know</a>

According to reports citing Gintsburg, six patients with <a href="https://www.healthandme.com/health-news/worlds-first-cancer-vaccine-by-moderna-merck-cuts-melanoma-recurrence-risk-by-42-cancer-spread-risk-by-38-article-156389310" data-type="tilCustomLink">melanoma</a> have received the personalised vaccine so far. The first has completed the treatment course, while the second is reportedly halfway through a course involving 10 administrations. Four other patients have also begun treatment.

Russian specialists expect to treat around 20 patients at the Herzen Moscow Research Institute of Oncology by the end of 2026. The country's Health Ministry has reportedly allocated funding for the treatment and follow-up of 120 patients during 2026 and 2027.

Recreational Drugs, Steroids & Birth Control: Expert Explains Why Strokes Are Arriving Earlier

Even though the findings are promising, they should not be interpreted as evidence of a cancer cure. The current update concerns one patient with <span><a href="https://www.healthandme.com/health/melanoma">melanoma</a></span>, a type of <a href="https://www.healthandme.com/health-wellness/norah-odonnells-skin-cancer-journey-her-dermatologist-warns-against-tanning-beds-sunburns-article-156387379" data-type="tilCustomLink">skin cancer</a>. Although doctors have reported no new tumour growth during the follow-up period, four months is too short to establish whether the response will last or whether the cancer could return.

There are also currently no results from a large controlled clinical trial that could establish the vaccine's effectiveness, long-term safety or survival benefit. 

Outcomes across more patients will be essential to determine whether the treatment can consistently produce similar results.

Personalised cancer vaccines are an active area of research internationally. In October 2026, Moderna and Merck reported positive late-stage trial findings for their experimental personalised mRNA melanoma vaccine, used alongside the immunotherapy drug pembrolizumab (<span>Keytruda</span>). 

The trial involved more than 1,100 patients and found a reduction in the risk of melanoma recurrence or death compared with Keytruda alone. However, this is a different vaccine and treatment from Russia's NeoOncovac. 

Health Conditions A-Z

health

russias-mrna-cancer-vaccine-first-patient-completes-treatment-shows-no-new-tumours

russia

Melanoma

alexander gintsburg

neooncovac

keytruda

Russia mRNA Cancer Vaccine

mrna cancer vaccine

national medical research centre for radiology

kursiv

world-prematurity-day-from-nicu-to-nursery-the-hidden-psychological-toll-of-premature-birth-on-parents

World Prematurity Day: From NICU To Nursery, The Hidden Psychological Toll Of Premature Birth On Parents

aiims-performs-indias-first-open-fetal-surgery-to-repair-spina-bifida

AIIMS Delhi Performs India's First Open Fetal Surgery To Repair Spina Bifida

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Russia has reported a milestone in its experimental personalised cancer vaccine development. The first patient to complete treatment with the country's mRNA-based cancer vaccine is reportedly doing well as the follow-up scans showed no new tumour growth in the four months after completing therapy.The update was shared by Alexander Gintsburg, scientific director of Moscow's Gamaleya Research Institute of Epidemiology and Microbiology. According to a report published by Kursiv, the patient is undergoing monthly examinations at Russia's National Medical Research Centre for Radiology, including high-resolution CT scans. Doctors are paying attention to the lymph nodes where cancer is most likely to spread.The patient will remain under medical observation for the next three years. While the early findings are promising, they are based on a single patient's experience, which is a major limitation. Russia's Personalised mRNA Cancer VaccineAlso read: How The Conditions People Live In Can Quietly Shape Our Risk Of CancerThe treatment, known as NeoOncovac, is a personalised cancer vaccine developed with the help of messenger RNA (mRNA) technology.Unlike preventive vaccines that protect people against infections, therapeutic cancer vaccines are designed to help the immune system recognise and attack existing cancer cells.The vaccine is customised using the genetic characteristics of an individual's tumour. Researchers analyse tumour samples to identify specific mutations that could help distinguish cancer cells from healthy cells. The mRNA is then designed to instruct the body to produce these targets related to tumour, prompting the immune system to recognise and attack the cancer cells. It aims to make the immune response more specific to the patient's cancer rather than targeting all cancer cells.Six Patients Received The Vaccine Also read: American Cancer Society Revises Prostate Cancer Screening Guidelines: What You Need To KnowAccording to reports citing Gintsburg, six patients with melanoma have received the personalised vaccine so far. The first has completed the treatment course, while the second is reportedly halfway through a course involving 10 administrations. Four other patients have also begun treatment.Russian specialists expect to treat around 20 patients at the Herzen Moscow Research Institute of Oncology by the end of 2026. The country's Health Ministry has reportedly allocated funding for the treatment and follow-up of 120 patients during 2026 and 2027.          Even though the findings are promising, they should not be interpreted as evidence of a cancer cure. The current update concerns one patient with melanoma, a type of skin cancer. Although doctors have reported no new tumour growth during the follow-up period, four months is too short to establish whether the response will last or whether the cancer could return.There are also currently no results from a large controlled clinical trial that could establish the vaccine's effectiveness, long-term safety or survival benefit. Outcomes across more patients will be essential to determine whether the treatment can consistently produce similar results.Personalised cancer vaccines are an active area of research internationally. In October 2026, Moderna and Merck reported positive late-stage trial findings for their experimental personalised mRNA melanoma vaccine, used alongside the immunotherapy drug pembrolizumab (Keytruda). The trial involved more than 1,100 patients and found a reduction in the risk of melanoma recurrence or death compared with Keytruda alone. However, this is a different vaccine and treatment from Russia's NeoOncovac. 